We understand that new treatments like retatrutide are exciting, but until they receive proper approvals, we remain committed to offering solutions that are both cutting-edge and trustworthy
Modifications of position 12 in a parathyroid hormone and parathyroid hormone-related protein: toward the design of highly potent antagonists
The trial's expansion to 104 weeks showed up to 30.3% weight loss, further solidifying its promise
Storage conditions significantly affect peptide stability
Looking forwards: future avenues of research for incretin biology Looking forwards: future avenues of research for incretin biology Several factors hampered (and continue to challenge) clinical development of GLP agonist therapies
A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes